We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novartis Announces Data on Tafinlar, Mekinist & Piqray at ESMO
Read MoreHide Full Article
Novartis (NVS - Free Report) announced disappointing detailed results from the phase III COMBI-i study at the European Society of Medical Oncology (ESMO) Virtual Congress 2020.
The COMBI-i was a phase III, double-blinded global study (NCT02967692) evaluating the investigational anti-PD1 therapy spartalizumab in combination with Tafinlar + Mekinist compared to Tafinlar + Mekinist and placebo as first-line therapy in patients with unresectable (Stage IIIC) or metastatic (Stage IV) BRAF V600E/K mutation-positive cutaneous melanoma.
While the combination of Tafinlar + Mekinist is approved for the treatment of patients with unresectable or metastatic BRAF-mutated melanoma by the FDA and the European Commission, spartalizumab is an investigational monoclonal antibody directed against the human programmed death-1 (PD-1) receptor.
The trial did not meet its primary endpoint of investigator-assessed progression-free survival (PFS) for patients treated with the investigational triplet therapy.
Nevertheless, Novartis will continue with its spartalizumab development program, evaluating the immunotherapy in combination with other anti-cancer agents.
After having gone through a series of restructuring moves, Novartis looks to strengthen its core pharma business and approval of new therapies will help its cause.
Separately, the company also announced results of the final overall survival (OS) analysis from the SOLAR-1 trial at the ESMO.
The study evaluated breast cancer drug, Piqray (alpelisib), in combination with AstraZeneca’s (AZN - Free Report) Faslodex (fulvestrant) compared to Faslodex alone, in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer patients with tumors harboring a PIK3CA mutation.
Data showed that Piqray plus Faslodex demonstrated 8 months of clinically relevant improvement in OS in HR+/HER2- advanced breast cancer (aBC) patients with a PIK3CA mutation compared to Faslodex alone. However, the difference between the arms did not reach the prespecified threshold of statistical significance set for the secondary objective of OS in patients with PIK3CA-mutated breast cancer. A more than 14-month OS improvement was observed in patients with lung or liver metastases, which signify more aggressive disease.
We note that Piqray was approved in July 2020 in combination with Faslodex for the treatment of postmenopausal women, and men, with HR+/HER2- locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy.
The stock has lost 5.8% in the year so far against the industry’s growth of 1.7%.
Solid performance of key drugs like Cosentyx and Entresto and contributions from gene therapy, Zolgensma, have boosted Novartis’ top line but competition is stiff.
Cosentyx maintains a positive momentum for the company on recent label expansions, despite stiff competition from AbbVie’s (ABBV - Free Report) Humira and Johnson & Johnson’s (JNJ - Free Report) Tremfya.
New launches like Piqray and Beovu too are projected to fuel growth for Novartis.
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
With users in 180 countries and soaring revenues, it’s set to thrive on remote working long after the pandemic ends. No wonder it recently offered a stunning $600 million stock buy-back plan.
The sky’s the limit for this emerging tech giant. And the earlier you get in, the greater your potential gain.
Image: Bigstock
Novartis Announces Data on Tafinlar, Mekinist & Piqray at ESMO
Novartis (NVS - Free Report) announced disappointing detailed results from the phase III COMBI-i study at the European Society of Medical Oncology (ESMO) Virtual Congress 2020.
The COMBI-i was a phase III, double-blinded global study (NCT02967692) evaluating the investigational anti-PD1 therapy spartalizumab in combination with Tafinlar + Mekinist compared to Tafinlar + Mekinist and placebo as first-line therapy in patients with unresectable (Stage IIIC) or metastatic (Stage IV) BRAF V600E/K mutation-positive cutaneous melanoma.
While the combination of Tafinlar + Mekinist is approved for the treatment of patients with unresectable or metastatic BRAF-mutated melanoma by the FDA and the European Commission, spartalizumab is an investigational monoclonal antibody directed against the human programmed death-1 (PD-1) receptor.
The trial did not meet its primary endpoint of investigator-assessed progression-free survival (PFS) for patients treated with the investigational triplet therapy.
Nevertheless, Novartis will continue with its spartalizumab development program, evaluating the immunotherapy in combination with other anti-cancer agents.
After having gone through a series of restructuring moves, Novartis looks to strengthen its core pharma business and approval of new therapies will help its cause.
Separately, the company also announced results of the final overall survival (OS) analysis from the SOLAR-1 trial at the ESMO.
The study evaluated breast cancer drug, Piqray (alpelisib), in combination with AstraZeneca’s (AZN - Free Report) Faslodex (fulvestrant) compared to Faslodex alone, in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer patients with tumors harboring a PIK3CA mutation.
Data showed that Piqray plus Faslodex demonstrated 8 months of clinically relevant improvement in OS in HR+/HER2- advanced breast cancer (aBC) patients with a PIK3CA mutation compared to Faslodex alone. However, the difference between the arms did not reach the prespecified threshold of statistical significance set for the secondary objective of OS in patients with PIK3CA-mutated breast cancer. A more than 14-month OS improvement was observed in patients with lung or liver metastases, which signify more aggressive disease.
We note that Piqray was approved in July 2020 in combination with Faslodex for the treatment of postmenopausal women, and men, with HR+/HER2- locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy.
The stock has lost 5.8% in the year so far against the industry’s growth of 1.7%.
Solid performance of key drugs like Cosentyx and Entresto and contributions from gene therapy, Zolgensma, have boosted Novartis’ top line but competition is stiff.
Cosentyx maintains a positive momentum for the company on recent label expansions, despite stiff competition from AbbVie’s (ABBV - Free Report) Humira and Johnson & Johnson’s (JNJ - Free Report) Tremfya.
New launches like Piqray and Beovu too are projected to fuel growth for Novartis.
Novartis currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks’ Single Best Pick to Double
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
With users in 180 countries and soaring revenues, it’s set to thrive on remote working long after the pandemic ends. No wonder it recently offered a stunning $600 million stock buy-back plan.
The sky’s the limit for this emerging tech giant. And the earlier you get in, the greater your potential gain.
Click Here, See It Free >>